We Ranked the 3 Most-Hyped Longevity Antioxidants of 2026 – Rovina
The two chiefs
House chief · 7.5/10
sponsored category ranking on the seller's own store · cold paid traffic from longevity interest · adults who take or follow antioxidants (CoQ10, resveratrol, vitamins) and have not met astaxanthin · solution-aware · whole-cell coverage: both membrane zones and the mitochondria
Lead: Discovery lead told by a sceptic. Grade A-minus: it earns the hearing, delays the reveal and lands it in seven words; the 'I' and the 'we' are never sorted out.
Offer: The same block as the sibling page: two-for-one as a percentage, a daily cost, a 90-day guarantee, a rating, a crowd. No price in dollars and no reason for the discount.
Close: Offer, button, trust line, a reasoned guarantee, and a close built on regret in advance. No invented deadline.
Throughline: Shared scepticism, recognition of one's own signs, relief at a single answer, then a gentle fear of having waited. It breaks once, where the card's label voice interrupts the narrator.
Strongest
- the category frame itself: the reader's cabinet is the field and the seller's product is the only thing that can be bought
- criteria about the molecule's nature, planted early and cashed late (entries 12, 35)
- rivals praised, limited and given a role (entries 17, 20)
- the potency figure spent late and made secondary (entry 30)
- one imperfect score in the table (entry 25)
Weakest
- no argument for why this astaxanthin (entry 23)
- a team, hours and formulas that cannot be checked, and a laboratory picture (entries 1, 6)
- nothing named in the science (entries 31, 33)
- one fifth of the page shared with a sibling
- a heading that promises a customer's results (entry 37)
Craft chief · REVISE
The closest of the three to singing: a sceptic talks the reader round, and then a product card interrupts in another voice.
Strongest
- entry 8: a sceptic's lead that agrees with the reader's distrust before it asks for belief
- entry 9: three familiar supplements and one picture of doors
- entries 12 and 35: requirements planted at 23% and cashed at 72% by direct callback
- entry 17: praise, two limits, and a role that lets the reader keep the bottle
- entry 36: an unedited review that sounds like a person
Weakest
- entry 23: the jump from winning molecule to seller's brand, unargued
- entry 11: a paragraph stitched from two, with its lead-in repeated
- entries 27, 31, 40: blocks cloned from the sibling page
- entry 6: a laboratory picture for a literature review
001 PASS · entries 8-9 vary their length and land short; the card and the research block (entries 26, 31) are flatter. · 002 PASS · a complete movement with a full close (entries 37-42). · 003 PASS·noted · plain; the technical word in entry 10 is glossed; the species name in entry 26 is not. · 004 PASS · two lines of suspense before the reveal (entry 8), a hinge question (entry 15), a direct callback (entry 35); no comfortable exit before the winner. · 005 PASS·noted · the headline's ranking is delivered; its verb for what was done grows into testing in entry 15 and a laboratory picture (entry 6), which the text does not support. · 006 PASS · the signs in entry 11 can be pictured; the doors in entry 9 are concrete. For the guard: the potency multiples, 100,000 people, 300 hours, 50 formulas. · 007 PASS·noted · the capture shows the deck highlighted and the kicker in italics. · 008 PASS·noted · entry 11 repeats its own lead-in phrase; the research block is cloned. Cost: a careful reader notices the stitching. · 009 PASS · the lead is a discovery story with a person, an expectation and a reversal, and its point is the offer's premise; whether the team exists is for the guard. · 010 PASS · the lead is spoken; entry 17 ends on two fragments a person would say. · 011 PASS·noted · no picture has alt text; the hero shows a laboratory and no product; the offer and buttons are in text. · 012 PASS·noted · entry 42 ships a leftover phrase; the fine print (entry 43) is present and stock. · 013 PASS · the first line sides with the reader's distrust; the signs in entry 11 are the reader's own. · 014 PASS · recognition, a small fear, relief at an answer, regret in advance at the close (entry 41). · 015 REVISE · em dashes throughout; throat-clearing frames at entries 8 and 30; contrast flips at entries 8, 33 and 41. Tier 1 in copy someone else wrote: flagged, not rewritten. · 016 PASS · nothing on the first screen needs prior knowledge, and the winner's molecule is explained before it is named. · 017 PASS · emotion (tired of hype), curiosity (which one) and stakes (half the cell unguarded) are present by entry 9. · 018 PASS · colour: half the cell and the doors (entries 8, 9); potency made secondary to place (entry 30); the unedited testimonial (entry 36). · 019 PASS·noted · the first-person passages have a real-sounding roughness in the lead and none in entries 30 and 40. · 020 REVISE · about a fifth of the words recur on the sibling review page, among them the trade-offs, the research block, the offer and the guarantee (entries 27, 31, 37, 40). Cost: a reader who meets both sees a template. · 021 N/A · not an email sequence. · 022 PASS·noted · the two fragments closing entry 17 and the three closing entry 35 are earned staccato. · 023 PASS·noted · the first screen names a ranking of molecules; the object the buyer leaves with appears at 44% and its price never in dollars. · 024 N/A · no verb hands the product a decision the buyer owns. · 025 PASS·noted · value scores four here and five on the sibling page for one price; a review score of five against 4.4 stars (entries 25, 39); four requirements set and five different rows scored. Notes for the guard.
Take
- Rank categories and let the reader's cabinet be the field (entries 3, 16, 19). Ours, inside the gate: the multivitamin, vitamin C and vitamin E against The Cell Shield (p3, r3, m2, m3). It reaches the reader p7 describes. The angle needs David's verdict first (CL-20).
- The sceptic's lead: agree with the distrust, confess the wrong assumption, delay the reveal, land it short (entry 8), then prove it at once with supplements the reader takes (entry 9).
- Criteria about what the thing is, planted early and cashed late by direct callback (entries 12, 35). CS-P1 sets tests and never returns to them as a list.
- Praise, limit, role: each rival keeps a place in the reader's routine (entry 17). Ours is b9 and r23.
- Spend the famous number late and make it secondary to where the molecule works (entry 30): our angle CS-A06.
- One imperfect score in the winner's table (entry 25). CS-P1 already has it (7.5 on cost per day).
- An unedited review from a buyer of our reader's age, placed before the offer (entry 36).
- A close built on regret in advance with a number in it (entry 41), using our own clock (r7, b6).
- One recurring picture for the idea (the doors, entries 9 and 35). Ours could be the shield across the membrane.
- Disclosure at both ends of the page (entries 1, 43).
Leave
- The unargued jump from the winning molecule to the seller's brand (entry 23). Our page has to say why this astaxanthin: b7, c4, c1, c3.
- Every claim about CoQ10 and resveratrol, and the CoQ10 potency multiple (entries 9, 17, 20, 30): none is in our gate.
- FABRICATION RISK: the unnamed team, its hours and formula counts, and the laboratory pictures (entries 1, 6, 23). We tested nothing in a laboratory.
- FABRICATION: a score table with no method, and a review score that contradicts the printed rating (entries 25, 39).
- The claim of a first in the kicker (entry 2).
- The 90-against-30-day argument (entries 27, 40): our guarantee is 30 days.
- Carrier-oil and absorption superiority (entries 25, 26): banned for us (b8).
- Build-up in tissue as a criterion (entry 12): not in our gate; our timeline claims are r7, b6, r8.
- Their label for the first score row: never in our customer copy (CL-02). The noun is The Cell Shield.
- Skin first in the list of signs and benefits (entries 11, 31): our page leads with kidneys, brain, eyes and joints (CL-04).
- A heading that promises the reader a customer's results (entry 37), and the cloned blocks and stitching errors (entries 11, 27, 31, 40).
Line by line · 43 entries
Every line is described in our words; the page's own text stays on the page (open it beside this table). Shaded rows carry the most pull.
| # | Beat | What the line does | Lever · reader | Why here | Craft | On our page |
|---|---|---|---|---|---|---|
| 1 0.2% | authority-stamp 2× h2 · 24 w | The author block opens with an advertiser-disclosure line in grey italics, then credits an editorial research team with over 300 hours of research and more than 50 formulas reviewed, and gives an update date in May 2026. | borrowed-authorityspecificitycandor solution-aware | The disclosure sits where a byline's job title would, so it is read as part of the credentials. Hours and a formula count stand in for a named expert. | FABRICATION RISK: a team with no names. The hours and the count cannot be checked, and the page ranks three categories, not 50 formulas. The thumbnail in the capture is a laboratory bench and not a person. | rewrite-claim CS-P1 has an editor byline and a footer disclosure. For a category page the honest stamp is what was read: the studies our gate rests on. CL-14 forbids invented authorities, and a laboratory picture implies testing we did not do. |
| 2 1.2% | deck quote · 21 w | A quoted kicker above the headline says 2026 is the first year in which ageing from within is something a person can act on. | hopecuriosity-gappattern-interrupt solution-aware | It comes before the headline and frames the page as news about ageing and not as a product comparison. The reader it selects cares about longevity in general and may never have heard of astaxanthin. | Twenty-one words with a quotation inside a quotation and no speaker. The claim of a first rests on nothing. | rewrite-claim CS-P1 has no kicker. Our register for this idea is r24: age with strength, clarity and independence. No claim of a first. r24 |
| 3 2.0% | hook-headline h2 · 15 w | The headline says the three most talked-about longevity antioxidants of the year were ranked and one finished far ahead. | curiosity-gapspecificitycontrast solution-aware | The adjective sides with the sceptical reader before any claim is made. The ranked things are categories, so the reader's own supplement is probably among them, and the winner is unnamed. | Fifteen words. One compound adjective does the work: it promises debunking. The second clause is a small race image. | keep-structure CS-P1 ranks five astaxanthin products and so speaks only to a reader already shopping for astaxanthin. A category headline would reach the reader p7 describes, who has never heard of it. Ours would rank what is in our reader's cabinet (the multivitamin, vitamin C, vitamin E) on p3, r3 and m2, with the organs explicit (CL-04). CL-20: the angle (CS-A02 or CS-A06, both still candidates) needs David's verdict first. p7p3r3m2 |
| 4 3.0% | deck h2 · 20 w | The deck promises what the science says about each of the three, and one molecule able to do what the others are not. | open-loopexclusivityborrowed-authority solution-aware | It withholds both the winner's name and its ability. The reader has to read the lead to learn what the others cannot do. | Twenty words, highlighted in the capture, one dash. An adverb props the first clause. | keep-structure CS-P1's subhead counts tests and names organs. For a category page the deck would promise the one that covers the whole cell (m2) and name the organs it is studied for. m2 |
| 5 3.9% | proof-social fine · 9 w | A small coloured line says over 100,000 people have already changed over. | social-proofconsensus solution-aware | It stands inside the first screen, under the deck. The line does not say what the crowd changed to, which keeps the winner unnamed and the claim beyond checking. | Nine words. The same number as on the sibling page, with a different verb. | swap-proof CS-P1 shows 2,847 verified customers in its sidebar (the four-digit form CL-11 asks for). A count in the first screen needs the store's real number. r17 |
| 6 4.2% | image img | The hero picture, with no alt text. In the capture three people in white coats work at a laboratory table with a microscope, a laptop and rows of vials. No product is shown. | borrowed-authority solution-aware | It follows the crowd line and closes the first screen on a scene of measurement. With no product in it, the page still looks like an inquiry. | The picture implies bench testing of the three antioxidants; the text below describes reading the literature. It has the over-clean look of a generated image. | drop No laboratory picture: we ran no lab comparison. CS-P1's hero is the bag. A category page could open on the cabinet of bottles our reader owns. |
| 7 6.2% | cta cta · 5 w | A full-width dark button offers the top pick; it jumps down the page to the winner's card. | easecuriosity-gap solution-aware | It stands at 6%, before any body copy. The reader who taps lands on the only thing on the page that can be bought. | Four words and an arrow. It names a rank and no molecule. | keep-structure CS-P1 has no early jump button and does not need one while its winner is the first card. A winner-last category page would. |
| 8 6.6% | turning-point p · 179 w | Sympathy for a reader tired of influencer breakthroughs; the team's long-postponed reading of the literature; their expectation that antioxidants are all alike; the surprise that most guard only half the cell, a watery zone or a fatty one. | identificationcandorstory-transportcuriosity-gapnew-mechanism solution-aware | The page has to earn a hearing from a reader who distrusts longevity claims, so it begins by agreeing with the distrust. The team's own wrong assumption mirrors the reader's, which lets the reader change mind without losing face. The flaw is named only after that. | The best lead of the store's three rankings. Spoken register, set in short paragraphs in the capture (the extraction joins them into one row of 179 words), with a three-beat list of what the team did. Two lines of suspense delay the reveal, which then takes seven words. The narrator is 'I' for one line and 'we' after. | swap-mechanism CS-P1's intro states the same flaw in three sentences and has no path of discovery. The reveal is ours by right: ordinary antioxidants guard only part of the cell (p3), and vitamins stay in the bloodstream while astaxanthin crosses the cell barrier (r5). Explain first, then name The Cell Shield (CL-07). A zero-narrator page (L-01) tells it as what the reading found. p3r5r3 |
| 9 14.6% | villain-reveal p · 51 w | Three named examples: vitamin C is confined to the water zone, vitamin E to the fatty membrane, CoQ10 largely to the fat side. A closing image has each guarding one door and leaving the other open. | specificitycontrastcommon-enemymirroring solution-aware | Examples follow the claim at once, while the reader is asking which antioxidants. Two vitamins come first because nearly everyone takes them; the third is one of the ranked categories, so the ranking has begun before the list. | Three parallel sentences and then a picture of doors. The door image is the page's best metaphor and returns in entry 35. | rewrite-claim Ours holds for two of the three: vitamin C works outside the cell and vitamin E sits on the membrane surface (p3). The gate holds nothing on CoQ10, so that sentence needs a new gate entry or stays out. CS-P1's intro names vitamin C and vitamin E without saying where each works. p3 |
| 10 16.2% | stakes p · 26 w | While half the cell is unguarded, the part said to age first, the mitochondria, glossed as the cell's power plants, goes on being damaged. | fear-of-declineloss-aversionnew-mechanism solution-aware | After the flaw comes its price. The line introduces the mitochondria, which become the second of the four requirements a few lines on. | One sentence of 26 words with two dashes and a gloss for the technical word. The verb for damage keeps the register spoken. | rewrite-claim Ours: mitochondrial energy (r13) and reactive oxygen species from modern diet and modern life (r1). CS-P1 says the inside of the cell stays open and does not name the mitochondria. r13r1 |
| 11 17.5% | symptom-mirror h2 · p · 123 w | A heading calls oxidative ageing predictable. The paragraph lists daily sources of damage, names the signs (dull skin, slow recovery, afternoon slump, stiff joints, running below full power), and says famous antioxidants fail one or more of four requirements. | mirroringfear-of-declineidentificationopen-loop solution-aware | Signs come after the cause, so each is read as evidence for it. The list is broad enough for any adult over 40 to find two. The paragraph ends on a colon that hands over to the criteria. | The signs are concrete and the last is the most human. The paragraph then changes subject twice and ends by stating its lead-in phrase twice over, a stitching error. | rewrite-claim CS-P1's opening names organs; its signs (the afternoon slump, small print, bloating) appear only in the timeline after the cards. Ours for the senior reader: the noon crash (r7), brain fog (r6), stiff joints as rusting inside the cartilage cells (p5), eyes sold as relief and never as a screen problem (b3; p4 is banned). Skin is the seventh pillar and not the first. r7r6p5b3r1 |
| 12 23.0% | ranking-criteria 4× p · 44 w | Four requirements for a true longevity antioxidant: coverage of the membrane's water side and fat side, access to the mitochondria, a clinical dose in usable form, and accumulation in tissue over the weeks. | reason-whyspecificitycommitmentnew-mechanism solution-aware | Criteria come before any category is judged. Two of the four are properties a molecule has or lacks for good, so the rivals cannot pass whatever brand or dose is chosen. The other two (dose, build-up) prepare the step from molecule to product. | Four lines, each a verb phrase, a dash and a reason, in nine to fifteen words. The order runs from the cell outwards to the calendar. | rewrite-claim CS-P1's criteria are label tests (dose in one softgel, lab tested, cost per day). A category page needs cell tests: spans the whole membrane (m2), crosses the cell barrier (r5), the full 12 mg (b7), one softgel a day (b9). The gate has no claim about build-up in tissue; our timeline claims are r7, b6 and r8. m2r5b7b9 |
| 13 25.0% | ranking-criteria p · 9 w | A two-sentence tally: most remedies miss one requirement and many miss two. | consensusloss-aversion solution-aware | Last line before the hinge. It tells the reader to expect failures, so the two rivals' shortfalls will look like the rule and the winner like the exception. | Nine words. The noun for the products is one the page uses nowhere else, and an odd one for antioxidants. | keep-structure CS-P1's method box ends on the routine test and has no tally. Ours would be c1: about 64% of unverified astaxanthin products fail potency testing. c1 |
| 14 25.6% | image img | A three-by-two picture with no alt text follows the four requirements. Its content was not captured; by position it most likely illustrates the two zones or the four requirements. | ease solution-aware | It stands between the criteria and the hinge question, the same slot as on the sibling page. | No alt text. A diagram of a membrane would be the most useful picture on the page; whether this is one cannot be told from the rows. | swap-mechanism CS-P1 has no diagram wired; BRAND.md records cell and organ picture pairs awaiting a verdict on the Studio. A plain picture of a membrane with vitamin C outside, vitamin E on the surface and astaxanthin across it would carry The Cell Shield for a reader who skips the text (p3, m2). Alt text is customer copy. p3m2 |
| 15 28.6% | ranking-criteria 2× h2 · video · 21 w | A question asks which of the three tested passes the bar, with a down arrow and a promise to show the findings. A short wide video strip sits beside it, and a two-word title opens the rankings. | open-loopcuriosity-gap solution-aware | At 28% the requirements are agreed. The narrator's promise to show what was found makes the list a report and not a pitch. | Nineteen words with an arrow glyph. The verb claims testing, where the lead described reading. The video's content was not captured. | keep-structure CS-P1 has no hinge line between its method box and its first card. One question would do. Our verb is read or compared, never tested. |
| 16 29.7% | ranked-entry h2 · img · 7 w | Silver medal, second place: CoQ10, nicknamed the classic for cellular energy, with a small picture. No brand and no grade. | identificationcontrast solution-aware | The list starts at second place. The category has no brand attached, so the reader's own bottle is the one being judged, whoever made it. | Seven words. The nickname is respectful. There is no letter grade on this page, unlike the brand rankings: a molecule has no label to grade. | rewrite-claim No CoQ10 claim is in our gate. Our second place would be vitamin E (on the membrane surface, p3) or the daily multivitamin (r3). p3r3 |
| 17 31.6% | ranked-entry 2× p · 85 w | CoQ10 is granted its reputation for mitochondrial energy and heart health. Two limits follow: it works mainly on the fatty side, and the body's own levels fall with age. The verdict: a good supporting player, not the centrepiece. | candorcontrastfear-of-declinecommitment solution-aware | The reader most likely to be here takes CoQ10. Praise first keeps that reader; the verdict lets them keep the bottle and still need something more. No brand is named, so no seller defends it and there is nowhere else to click. | 72 words that end on two fragments, the second a shrug. The second limit is a non sequitur: falling natural levels are a reason to supplement and not a flaw in the supplement. | rewrite-claim No CoQ10 claim is in our gate. Ours for second place: vitamin E sits on the membrane surface (p3), or the multivitamin is underdosed and cannot get into the cells (r3). The friendly frame is ours already: one softgel in place of juggling dozens (r23), replacing nothing in the routine and protecting everything in it (b9). p3r3r23b9 |
| 18 34.8% | cta 2× cta · 5 w | A button under the CoQ10 card leads to the winner's product page, naming it only by rank. | curiosity-gapease solution-aware | It stands at 35%, under a card that reviewed a molecule. There is no rival product to link to, so the only exit on the page is the seller's. | Four words and an arrow, split over two lines of markup. The same label as on the sibling page. | keep-structure CS-P1's rival cards carry no button. On a category page a link to our top pick under each card costs nothing and sends no reader to a rival. |
| 19 35.5% | ranked-entry h2 · img · 7 w | Bronze medal, third place: resveratrol, nicknamed for red wine, with a small picture. No brand and no grade. | contrastpattern-interrupt solution-aware | Third place is read directly before the winner. The most famous name of the three is placed there so that fame itself is what the winner is seen against. | Seven words. The nickname recalls the news story most readers know the molecule from. | rewrite-claim No resveratrol claim is in our gate. Our third place would be vitamin C, the antioxidant every reader knows (p3, m3). p3m3 |
| 20 37.4% | ranked-entry 2× p · 89 w | Resveratrol is introduced through the red-wine headlines. Its hype and lab research are granted; the problem named is absorption, with a large part of each dose lost in digestion. The verdict: large reputation, weak delivery. | contrastspecificitycandorloss-aversion solution-aware | The reader meets first place having just learned that fame and laboratory results are not the same as results in a body. That prepares the winner's claim to repeated human studies in entry 33. | The contrast between a laboratory dish and a digestive system is the best line in the card. The verdict is two fragments and a dash. | rewrite-claim No resveratrol claim is in our gate. Our third place would be vitamin C: it works outside the cell (p3), and astaxanthin has about 6,000 times its singlet-oxygen quenching power (m3). p3m3 |
| 21 41.0% | cta 2× cta · 5 w | The same rank-only button under the resveratrol card. | curiosity-gapease solution-aware | It stands at 41%, a few lines above the winner's medal. A reader who has seen both rivals fail is offered the answer one tap early. | Identical to entry 18. | keep-structure As for entry 18. |
| 22 41.7% | image img | A small square picture with no alt text stands ahead of the winner's heading. Its content was not captured; by size and slot it is most likely a seal or award badge. | anchoring solution-aware | Same slot as on the sibling page: a boundary between the rivals and the medal. | No alt text. If it is an award seal, nothing on the page says who gave the award. | drop CS-P1 marks its winner with a ribbon in text. No seal that implies an outside award. |
| 23 43.0% | ranked-entry 4× h2 · p · img · 46 w | Gold medal, billed as the top pick of the research desk: the seller's Sunglow 12 mg softgel, a brand where the rivals were molecules. A pull quote pairs the 6,000-times-vitamin-C figure with whole-cell protection. Team credit and product picture follow. | loop-closedexclusivityspecificityborrowed-authority product-aware | Second and third place were categories; first place is a brand. The switch happens at the peak of the reader's curiosity, when the question is which molecule, and the answer arrives with a name and a picture attached. The reader is not invited to ask which astaxanthin. | The leap is unargued: nothing says why this astaxanthin and not another. The quotation pairs the potency number with the place of action, the pairing our angle CS-A06 is built on. FABRICATION RISK: the team credit repeats the hours and the formula count. | swap-mechanism On our page first place is The Cell Shield: CellScience Astaxanthin 12 mg, one softgel a day. Argue the step from molecule to product, which this page skips: the full 12 mg (b7), natural microalgae (c4), every batch lab tested when about 64% of unverified products fail (c1, c3). m3 and m2 carry the pull quote. m2m3b7c4c1c3 |
| 24 47.7% | cta cta · 3 w | A three-word button in capitals asks the reader to try the product now. | easeurgency product-aware | It stands under the winner's picture and above the scores, as on the sibling page. A reader who came by the jump button at entry 7 meets a buy button before any argument. | Capitals, three words. It states no price, guarantee or noun. | swap-offer Ours carries the noun and the 30-Day Money-Back Guarantee (CL-16, CL-09). |
| 25 48.2% | ranked-entry 10× p · 25 w | A five-row score table for the winner only: protection of both membrane zones, the 12 mg dose, absorption from an oil softgel, verified reviews, all at five out of five, and value at 33 cents a day at four. | specificitycandorsocial-proofanchoring product-aware | Only the winner is scored. The single four, on value, comes where the reader is most likely to object, so the table admits the objection before the reader raises it. | The row labels differ from the four requirements set earlier: getting to the mitochondria and building up in tissue have no row. The first row is labelled with the word our copy never uses. FABRICATION: no method, and the review score contradicts the 4.4 stars in entry 39. | keep-structure CS-P1 scores every product on three bars and gives itself 7.5 on cost per day, the same candour. A category table would score each antioxidant on the cell tests (m2, r5) and on dose (b7). The row for how it works carries the noun, The Cell Shield (CL-02). m2r5b7 |
| 26 51.1% | ranked-entry h2 · 5× p · 72 w | Five plus points: it spans the whole membrane so the entire cell is covered; the full 12 mg against a token 4 mg; natural microalgae and no synthetic copy; an organic coconut-oil softgel; a clean label. | reason-whyspecificitycontrast product-aware | The first line is the molecule's property and the next four are the product's. The list walks the reader from astaxanthin in general to this softgel without marking the step. | Label, dash, gloss. The second line has the freshest phrase, a two-word picture of a dose added for the label's sake. Price has dropped off the list, in line with the four-out-of-five above. | rewrite-claim Ours: spans the whole membrane bilayer (m2), the full 12 mg against the 4 to 6 mg brands (b7), natural microalgae and no petrochemical synthetic (c4, r16), closed-bioreactor purity (c5), every batch lab tested (c3). No carrier-oil line (b8). m2b7c4r16c5c3 |
| 27 55.3% | ranked-entry h2 · 2× p · 37 w | Two trade-offs, word for word as on the sibling page: it is sold online only, and its results build over four to six weeks, which a bracket gives as the reason the guarantee runs 90 days. | candorobjection-preemptrisk-reversalreason-why product-aware | Slowness is the strongest objection to a supplement. The seller raises it inside the winner's card and answers it in the same line. On this page the fourth requirement (build-up in tissue) has already taught the reader to expect it. | A true cost to the buyer, stated in a spoken aside. The block is cloned from the sibling page. | rewrite-claim CS-P1's list of things worth knowing has three honest limits and none about time. Ours: energy in weeks 1 to 2 (r7) and eye strain relief in 14 to 28 days (b6), both inside the 30-day guarantee; kidney labs are re-drawn at 8 to 12 weeks (r10), outside it. Say plainly what the window covers. r7b6r10 |
| 28 57.5% | cta cta · 4 w | A button invites the reader to claim the top-ranked product. | commitmentexclusivity product-aware | It stands at 58%, at the foot of the winner's card, after the trade-offs have been answered. | Four words. The same label as on the sibling page. | swap-offer CS-P1 closes its winner card with a full block: the noun, the per-bag price, free shipping and the 30-Day Money-Back Guarantee. Ours is stronger. |
| 29 58.3% | image img | A wide banner with no alt text separates the winner's card from the narrator's account. Its content was not captured. | ease product-aware | Same slot as on the sibling page: above it a ranking for the scanner, below it the reasons. | No alt text and no caption. | page-furniture CS-P1 needs no banner in this place. |
| 30 59.7% | differentiation h2 · 2× p · 95 w | Under a heading about the 6,000-times antioxidant, the narrator admits nearly skipping astaxanthin, gives its potency (about 6,000 times vitamin C, 800 times CoQ10, 550 times vitamin E) and says potency mattered less than where it works. | candorspecificitycontrastcuriosity-gapearned-authority product-aware | The potency figure is what the reader has seen in ads. It is given after the card, as a side fact, so the page gets its force and still keeps whole-cell coverage as the reason to buy. One of the three comparisons is against a ranked rival. | The confession opens with a throat-clearing frame. The numbers sit in one long sentence with two dashes and a colon. The last two sentences are short and turn the section. | rewrite-claim This is our angle CS-A06: the number matters because of where it works. Ours: about 6,000 times vitamin C and about 550 times vitamin E (m3), then the membrane (m2). The CoQ10 multiple is not in our gate. CS-P1 states the 6,000 figure in its intro without the turn. m3m2r15 |
| 31 63.6% | proof-study h2 · p · 62 w | A research heading, then the sibling page's counts and topics in one paragraph: over 70 human trials, 3,500 papers, and work on the skin, eye fatigue from screens, recovery after exercise and oxidative stress. | borrowed-authorityconsensusspecificity product-aware | The science arrives at 64%, after the ranking, as reassurance near the offer. On this page it also has to separate the winner from two rivals whose evidence was called thin. | Hedged verbs and nothing named: no journal, no trial, no year. Cloned from the sibling page with three words changed. | swap-proof CS-P1 has no research section. Ours: 60+ clinical studies (r14), human trials on wrinkle depth, elasticity and hydration (b1), the double-blind trial in screen workers (b3), the joint science (b4). x3 asks that Harvard-level language be paired with the actual journals. r14b1b3b4x3 |
| 32 66.7% | image img | A three-by-two picture with no alt text sits inside the research section. Its content was not captured. | ease product-aware | It splits the counts from the two sentences that interpret them. | No alt text and no caption; the text never refers to it. | swap-proof A real abstract screenshot beside our study claims (b1, b3) would be proof a reader can check; house law L-05 sets the standard for such screenshots. b1b3 |
| 33 68.7% | proof-study p · 18 w | One sentence stresses that the ingredient has been studied in people again and again and does not rest on a lone promising trial. | borrowed-authoritycontrastconsensus product-aware | It follows the counts and answers the verdict on resveratrol in entry 20: that molecule was promising and unproven in people, and this one is said to be proven repeatedly. | Eighteen words and a dash, built as a contrast flip. It is the one line in the research block that is not on the sibling page. | swap-proof Ours: 60+ clinical studies (r14) and human trials named by outcome (b1 skin, b3 eyes). CS-P1 does not make the point about repeated human evidence. r14b1b3 |
| 34 69.6% | disclosure p · 33 w | In body type, the narrator states that none of this is a claim to treat or cure, says flatly that it does neither, calls it an antioxidant, and names support for the cells as the base everything else rests on. | candorobjection-preempt product-aware | It is placed after the research and before the explanation of why the molecule works, where a careful reader starts to wonder whether the page is overclaiming. | Three sentences; the second has two words and is the bluntest line on the page. The last turns the disclaimer into a claim about foundations. | keep-structure CS-P1 has this in the things worth knowing, the kidney FAQ and the footer, and not as a spoken paragraph in the body. Worth adding beside the organ claims. |
| 35 71.0% | mechanism h2 · p · 147 w | The text recalls the four requirements and ticks them off: soluble in water and fat, so it spans the membrane; placed to shield the mitochondria; absorbed from an oil softgel; built up over weeks. One molecule for the whole cell. | loop-closednew-mechanismreason-whycommitment product-aware | The requirements were planted at 23% and are cashed at 72%. The reader who agreed to them then is reminded of that agreement by a direct question, and watches the winner pass each in the order given. | It opens with a question to the reader, the only one in the body. The door image from entry 9 returns. One good phrase describes the effect as a change of baseline and not a buzz. Near the end come two short fragments. One row of 140 words in the extraction. | swap-mechanism The Cell Shield slot, as a callback. Ours: spans the entire membrane (m2) where vitamin C and vitamin E cover part (p3); mitochondrial energy (r13); the full 12 mg in one softgel a day (b7, b9). CS-P1 sets three tests and never returns to them as a list; its closing heading only alludes to them. m2p3r13b7b9 |
| 36 77.2% | proof-social h2 · img · quote · p · 55 w | A heading, a square picture (not captured) and one quotation from an unnamed verified customer, a fit 73-year-old woman, pleased after a short time with changes in skin and energy and meaning to continue. Her typing errors are kept. | social-proofidentificationhope product-aware | It stands directly before the offer, as on the sibling page. Here the speaker's age does extra work: the lead spoke to a follower of longevity trends, and the proof shows who buys. | Unedited: three typing errors and a run-on sentence. It reads as a real review, the only text on the store's three rankings that does. Her age places the buyer in the seventies. | swap-proof She is our reader: 60s to 70s, active, wants energy (i2, r24, r7). CS-P1's comments are placeholders. House law P-10 asks for this texture: true to the persona, typing errors kept, never trimmed. Use only verbatim customer words. i2r24r7 |
| 37 82.7% | offer h2 · img · p · 23 w | A four-word question heading points back at the testimonial's results. A product picture follows, then the offer: two for the price of one, stated as up to 67% off. | commitmentanchoringhope most-aware | The deal is held until 83%, after proof and testimonial. The heading makes the testimonial the promise, so the offer reads as the price of that outcome. | The heading implies the reader will get the same results, which the fine print in entry 43 denies. The offer line gives a percentage and no price in dollars, and no reason for the discount. | swap-offer Ours: 1 bag $29.99, 3 bags $59.97, 5 bags $89.95, free shipping, read from 29next at build time (CL-10). x4 lets the 5-bag tier be called the lowest price ever. No heading that promises a customer's results. x4 |
| 38 86.1% | cta cta · 6 w | The main offer button: try the brand without risk for 90 days. | risk-reversalease most-aware | It follows the deal at once, at 86%. Offer, button and trust line form one block. | Six words. The same label as on the sibling page. | swap-offer CS-P1's buttons carry the noun and the 30-Day Money-Back Guarantee (CL-09). Check before traffic that the line under our button (one-time purchase, free shipping) matches the Try Before You Buy box the buttons land on (ob=c). |
| 39 86.4% | proof-social p · 9 w | A one-line trust strip under the button: the guarantee, a rating of 4.4 stars labelled excellent, and the 100,000-customer count. | risk-reversalsocial-proofconsensus most-aware | It sits directly under the button, where the eye rests before a tap. | Nine words. Identical to the sibling page. The rating is below the perfect review score in entry 25. | swap-proof CS-P1's proof bar has three items (30 days, 12 mg in one softgel, lab tested every batch) and its sidebar has a rating with a four-digit customer count (CL-11). Both numbers need to be the store's real ones before traffic. c3b7 |
| 40 87.4% | guarantee h2 · p · 121 w | The sibling page's guarantee argument, reframed as the detail that persuaded the narrator the brand knows its own long-term results: a compound needing four to six weeks, 90 days against the usual 30, and the two opposite bets. | risk-reversalreason-whycontrastcommon-enemy most-aware | It comes after the button, for the reader who did not tap. The fourth requirement and the second trade-off have both set the four-to-six-week clock, so the argument lands on prepared ground. | First person here, where the sibling page was impersonal. About nine tenths of the wording is shared with the sibling. 115 words in one row. | rewrite-claim CS-P1 states its guarantee in the FAQ and the buttons with no reason attached. Ours is the 30-Day Money-Back Guarantee, bag kept (CL-09), so this argument is aimed at brands like ours. Our reason has to differ: the first changes are due inside the window (energy in weeks 1 to 2, r7; eye strain relief in 14 to 28 days, b6). r7b6 |
| 41 92.1% | close h2 · img · p · 56 w | The close, under a heading and a picture, reframes the choice: the issue is whether to go on with half-protection. A start six weeks ago would be felt today, and the reader should not wait for 2027. | loss-aversionurgencyfuture-pacingloop-closed most-aware | It returns to the half-cell idea from the lead and to the six-week clock from the criteria, and joins them into a reason to start today. The year in the last line answers the year in the kicker. | A contrast flip carries the first two sentences. The line about six weeks ago is the strongest in the close: regret in advance, with a number. 53 words. | rewrite-claim CS-P1's close promises a difference on the next labs, which should go to the claims reviewer (r10, r11). The regret-in-advance move transfers with our clock: energy in the first two weeks (r7), eye strain relief in 14 to 28 days (b6). r7b6 |
| 42 96.8% | cta cta · p · 15 w | The last button repeats the 90-day trial. Under it a line lists the guarantee and two stock phrases, one of which belongs to skincare photography. | risk-reversalease most-aware | It is the last persuasive element, at 97%, followed only by fine print. | LEFTOVER: the last phrase of the line comes from a skin page's template, as on the sibling page. | swap-offer CS-P1's last button is followed by one line: one-time purchase, 30-Day Money-Back Guarantee, free shipping. |
| 43 97.9% | disclosure 3× p · 58 w | Three lines of fine print: results are individual and may not be typical; the standard FDA statement for supplements; and an advertiser disclosure saying whoever publishes the page may be paid when readers buy through its links. | candor most-aware | At the foot of the page, after the last button. Together with the line in the author block it frames the page with disclosure at both ends. | Stock wording. The disclosure speaks of a publisher being compensated, on a page hosted by the seller's own store. | page-furniture CS-P1's footer carries the supplement disclaimer, the ad disclosure and a caution for readers on blood thinners or with a kidney diagnosis (r28). Ours is fuller. r28 |